clarithromycin has been researched along with carbamazepine in 33 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (15.15) | 18.2507 |
2000's | 9 (27.27) | 29.6817 |
2010's | 15 (45.45) | 24.3611 |
2020's | 4 (12.12) | 2.80 |
Authors | Studies |
---|---|
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bharate, SS; Vishwakarma, RA | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Getz, HD; Metz, DC | 1 |
Boustany, RM; DeLong, GR; Loganbill, H; Nahouraii, R; Nohria, V; Stafstrom, CE | 1 |
Dammann, HG | 1 |
Kaneko, S; Ohkubo, T; Otani, K; Shimoyama, R; Sugawara, K; Yasui, N | 1 |
Alegre Herrera, S; Araujo Sanabria, J; Rubio Rubio, JM | 1 |
Badyal, DK; Garg, SK | 1 |
Delpierre, S; Karoubi, E; Lacaille, S; Leclercq, V; Legrain, S | 1 |
Akcay, A; Alkis, M; Bavbek, N; Kanbay, M; Turgut, F; Uz, E | 1 |
Coubes, P; Crespel, A; Gélisse, P; Halaili, E; Hillaire-Buys, D; Jean-Pastor, MJ; Vespignan, H | 1 |
Asmin, J; Escher, BI; Hollender, J; Kwon, JH; Steimen, I; Vermeirssen, EL | 1 |
De Saint Martin, A; Fischbach, M; Fothergill, H; Gerout, AC; Laugel, V; Perville, A; Santucci, R | 1 |
Baiocchi, C; Calza, P; Giancotti, V; Medana, C; Padovano, E | 1 |
Calza, P; Giancotti, V; Medana, C; Minero, C; Padovano, E | 1 |
Bianco, G; Buchicchio, A; Caniani, D; Masi, S; Sofo, A | 1 |
Aoki, H; Itai, S; Iwao, Y; Mizoguchi, M; Noguchi, S; Watanabe, M | 1 |
Hwang, SH; Jung, HJ; Kang, TW; Kim, K; Lee, KH; Na, TW | 1 |
Bianco, G; Bufo, SA; Caniani, D; Coviello, D; Cristina Lafiosca, M; Mancini, IM; Masi, S; Pascale, R; Scrano, L | 1 |
Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H | 1 |
Fernandes, TV; Langenhoff, A; Rijnaarts, H; Tizzani, R; Wu, K; Zweers, H | 1 |
Abraham, TL; Bedwell, DW; Hall, SD; Hansen, K; Rougée, LRA | 1 |
1 review(s) available for clarithromycin and carbamazepine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
32 other study(ies) available for clarithromycin and carbamazepine
Article | Year |
---|---|
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels.
Topics: Adult; Carbamazepine; Clarithromycin; Drug Interactions; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Tetracycline | 1995 |
Erythromycin-induced carbamazepine toxicity: a continuing problem.
Topics: Adolescent; Carbamazepine; Child; Child, Preschool; Clarithromycin; Drug Interactions; Epilepsy; Erythromycin; Female; Humans; Male | 1995 |
Therapy with omeprazole and clarithromycin increases serum carbamazepine levels in patients with H. pylori gastritis.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Carbamazepine; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 1996 |
Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients.
Topics: Aged; Anti-Bacterial Agents; Anticonvulsants; Bipolar Disorder; Carbamazepine; Central Nervous System Diseases; Clarithromycin; Drug Interactions; Female; Humans; Male; Middle Aged; Pneumonia; Psychotic Disorders | 1997 |
[Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia].
Topics: Anti-Bacterial Agents; Anticonvulsants; Carbamazepine; Clarithromycin; Drug Interactions; Humans; Hyponatremia; Male; Middle Aged; Nervous System Diseases | 1998 |
Effect of clarithromycin on the pharmacokinetics of carbamazepine in rhesus monkeys.
Topics: Animals; Anti-Bacterial Agents; Anticonvulsants; Carbamazepine; Clarithromycin; Drug Interactions; Macaca mulatta; Male | 2000 |
[Avoidable adverse event: carbamazepine encephalopathy when introducing clarithromycine].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimanic Agents; Bipolar Disorder; Brain Diseases; Bronchitis; Carbamazepine; Clarithromycin; Drug Interactions; Electroencephalography; Humans; Iatrogenic Disease; Male; Time Factors | 2005 |
Hyponatremia due to an additive effect of carbamazepine and clarithromycin.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Carbamazepine; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Epilepsy; Female; Humans; Hyponatremia; Sinusitis; Sodium | 2007 |
[Carbamazepine and clarithromycin: a clinically relevant drug interaction].
Topics: Adult; Aged; Anti-Bacterial Agents; Anticonvulsants; Carbamazepine; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Overdose; Epilepsies, Partial; Epilepsy; Epilepsy, Frontal Lobe; Female; Humans; Infant; Male | 2007 |
The role of hydrodynamics, matrix and sampling duration in passive sampling of polar compounds with Empore SDB-RPS disks.
Topics: Carbamazepine; Clarithromycin; Environmental Monitoring; Estrogens; Pharmaceutical Preparations; Rivers; Sulfamethoxazole; Water Movements; Water Pollutants, Chemical; Yeasts | 2008 |
The onset of acute oxcarbazepine toxicity related to prescription of clarithromycin in a child with refractory epilepsy.
Topics: Carbamazepine; Child; Clarithromycin; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Oxcarbazepine | 2010 |
Identification of the unknown transformation products derived from clarithromycin and carbamazepine using liquid chromatography/high-resolution mass spectrometry.
Topics: Carbamazepine; Carbon; Chromatography, Liquid; Clarithromycin; Hydroxylation; Mass Spectrometry; Photolysis; Water Pollutants, Chemical | 2012 |
Fate of selected pharmaceuticals in river waters.
Topics: Anti-Bacterial Agents; Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Clarithromycin; Environmental Monitoring; Italy; Lincomycin; Mass Spectrometry; Photolysis; Rivers; Water Pollutants, Chemical; Water Pollution, Chemical | 2013 |
Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD).
Topics: Biodegradation, Environmental; Carbamazepine; Chromatography, High Pressure Liquid; Chromatography, Liquid; Clarithromycin; Pleurotus; Spectrometry, Mass, Electrospray Ionization; Trichoderma; Wastewater; Water Pollutants, Chemical | 2016 |
Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal.
Topics: Carbamazepine; Clarithromycin; Crystallization; Esters; Fatty Acids; Nifedipine; Phase Transition; Transition Temperature | 2016 |
Distribution and ecological risk of pharmaceuticals in surface water of the Yeongsan river, Republic of Korea.
Topics: Carbamazepine; Chromatography, Liquid; Clarithromycin; Ecosystem; Environmental Monitoring; Naproxen; Pharmaceutical Preparations; Republic of Korea; Risk Assessment; Rivers; Sulfamethoxazole; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical | 2019 |
Validation of a liquid chromatography coupled with tandem mass spectrometry method for the determination of drugs in wastewater using a three-phase solvent system.
Topics: Amoxicillin; Carbamazepine; Chromatography, Liquid; Clarithromycin; Erythromycin; Metformin; Particle Size; Solvents; Surface Properties; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical | 2020 |
Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Topics: Adult; Alkynes; Benzoxazines; Body Mass Index; Carbamazepine; Clarithromycin; Computer Simulation; Contraceptives, Oral, Combined; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Humans; Itraconazole; Levonorgestrel; Models, Biological; Obesity; Rifampin; Sex Hormone-Binding Globulin | 2021 |
Removal processes of individual and a mixture of organic micropollutants in the presence of Scenedesmus obliquus.
Topics: Carbamazepine; Chlorophyceae; Clarithromycin; Diclofenac; Metoprolol; Microalgae; Scenedesmus; Wastewater; Water Pollutants, Chemical | 2022 |
Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4.
Topics: Carbamazepine; Clarithromycin; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Microsomes, Liver; Midazolam; Troleandomycin | 2023 |